강직성 척추염(AS) : 시장 전망, 역학, 경쟁 구도 시장 예측 리포트(2025-2035년)

Ankylosing Spondylitis (AS) Market Outlook

Thelansis's "Ankylosing Spondylitis (AS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Ankylosing Spondylitis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Ankylosing Spondylitis (AS) Overview

Ankylosing Spondylitis is a chronic immune-mediated spondyloarthropathy strongly associated with HLA-B27, characterized by enthesitis, sacroiliitis, and progressive spinal fusion driven by TNF and IL-17 pathway dysregulation. It presents with insidious inflammatory back pain, morning stiffness improving with activity, and variable peripheral joint, ocular, and cardiac involvement. Diagnosis combines clinical criteria, MRI sacroiliitis, and HLA-B27 testing; ASDAS and BASDAI scores alongside structural progression gauge severity. NSAIDs remain first-line; refractory disease warrants TNF inhibitors, IL-17A/F dual blockade with bimekizumab, or JAK inhibitors including upadacitinib. Regular mobility assessment and cardiovascular screening guide monitoring. Early advanced therapy, physiotherapy, and patient education preserve function and quality of life.

Key Highlights

• In Germany, the diagnosed ankylosing spondylitis patient pool is projected to increase from approximately 202,963 in 2025 to 216,565 by 2035.
• Ankylosing spondylitis remains a chronic inflammatory disease causing progressive spinal damage and reduced mobility.
• Early diagnosis and treatment are essential to slowing structural progression and preserving physical function.
• Biologic therapies and targeted treatments have significantly improved disease outcomes.
• Persistent disease activity and delayed diagnosis continue to represent key clinical challenges.

Market Overview

• The Germany ankylosing spondylitis market is projected to grow from approximately $1.2 BN to $2.1 BN by 2035.
• Market growth is supported by:
• Increasing adoption of biologics and targeted therapies
• Growing awareness and earlier disease diagnosis
• Market value growth is driven by long-term treatment duration and premium therapeutic options.
• Future growth will depend on next-generation immunomodulatory therapies and personalized treatment strategies.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Shenzhen Huishan Biotechnology Co., Ltd.
• Lynk Pharmaceuticals Co., Ltd.
• Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
• SPH-BIOCAD (HK) Limited
• UCB Biopharma SRL
• Suzhou Zelgen Biopharmaceuticals Co., Ltd.
• Akeso
• Janssen Research & Development, LLC
• Biocad
• Jiangsu Vcare Pharmaceutical Technology Co., Ltd.
• Johnson & Johnson Private Limited
• AbbVie
• XBiotech, Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)